Changeflow GovPing Pharma & Drug Safety Novel LXR Modulators with Bicyclic Core for Tre...
Routine Notice Added Final

Novel LXR Modulators with Bicyclic Core for Treating Dyslipidemias

Favicon for changeflow.com ChangeBridge: Patent Apps - Pharma (A61K)
Published March 26th, 2026
Detected March 27th, 2026
Email

Summary

The USPTO has published a new patent application, US20260083704A1, detailing novel LXR modulators with a bicyclic core for treating dyslipidemias and related metabolic disorders. The application was filed on May 1, 2025, and published on March 26, 2026.

What changed

This document is a publication of a United States patent application (US20260083704A1) filed by inventors associated with the development of novel compounds that act as Liver X Receptor (LXR) modulators. The application specifically describes compounds with a bicyclic core moiety and their potential use in the prophylaxis and/or treatment of dyslipidemias and other metabolic disorders associated with impaired lipid homeostasis.

As this is a patent application publication, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific therapeutic agents. Pharmaceutical and drug manufacturers should monitor patent filings in this area for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS

Application US20260083704A1 Kind: A1 Mar 26, 2026

Inventors

Archana VIJAYAKUMAR, Eisuke MURAKAMI, Claus KREMOSER, Jen-Chieh CHUANG, Steve WENG, Ryan Steven HUSS, G. Mani SUBRAMANIAN, Robert P. MYERS

Abstract

The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/or treatment of diseases which are associated with the modulation of LXR, for example, dyslipidemias. The present disclosure further relates to the use of the present compounds in the prophylaxis and/or treatment of metabolic disorders associated with an impairment in lipid homeostasis.

CPC Classifications

A61K 31/404 A61K 31/4155 A61K 31/416 A61K 31/4178 A61K 31/423 A61K 31/4245 A61K 31/427 A61K 31/437 A61K 31/439 A61K 31/4439 A61K 31/454 A61K 31/4709 A61K 31/496 A61K 31/497 A61P 1/16 A61P 3/06

Filing Date

2025-05-01

Application No.

19196617

View original document →

Named provisions

LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083704A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Medical Research

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.